These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20193338)

  • 1. [The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer].
    Yu YL; Zhu ZT; Li JP; Ha MW; Liu XM; Wu Q; Xing YD
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):937-40. PubMed ID: 20193338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
    Zhang L; Qu X; Teng Y; Shi J; Yu P; Sun T; Wang J; Zhu Z; Zhang X; Zhao M; Liu J; Jin B; Luo Y; Teng Z; Dong Y; Wen F; An Y; Yuan C; Chen T; Zhou L; Chen Y; Zhang J; Wang Z; Qu J; Jin F; Zhang J; Jin X; Xie X; Wang J; Man L; Fu L; Liu Y
    J Clin Oncol; 2017 Nov; 35(31):3558-3565. PubMed ID: 28854065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 regimen: results of a prospective randomized crossover study.
    Liu Y; Zhang J; Teng Y; Zhang L; Yu P; Jin B; Zhao M; Shi J; Liu S; Song N; Li Z
    Tumori; 2009; 95(6):691-6. PubMed ID: 20210231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
    Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
    Dong X; Huang J; Cao R; Liu L
    Med Oncol; 2011 Dec; 28(4):1425-9. PubMed ID: 20602263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
    Jørgensen M; Victor MA
    Acta Oncol; 1996; 35(2):159-63. PubMed ID: 8639310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
    Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
    Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
    Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
    Cao J; Ouyang Q; Wang S; Ragaz J; Wang X; Teng Y; Wang B; Wang Z; Zhang J; Wang L; Wu J; Shao Z; Hu X
    Invest New Drugs; 2020 Apr; 38(2):507-514. PubMed ID: 32036491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy.
    Han Z; Sun X; Jiang G; Du X
    J Coll Physicians Surg Pak; 2016 Nov; 26(11):900-903. PubMed ID: 27981924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.
    Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C
    Support Care Cancer; 2003 Aug; 11(8):516-21. PubMed ID: 12836088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.